Aminoadamantane derivatives as therapeutic agents
Abstract
The invention provides new para-amino amino derivative, wherein the prepared by the method, comprising the novel para-amino amino derivative, and using the derivative and treatment and prevention of diseases method. Use of the invention treatment of a disorder with multiple, comprising as follows: A topical or ischemia the oxygen content in this high composition for a disorder of a wound, having a composition, comprising the middle; the hypoglycemia, a topical ischemia of disease, a second wrestle the limit, huntington's a wound, the perinatal the oxygen content is too low, the compound wrestles the limit and hypoglycemia, dementiaThe of neurodegenerative disorder is amitriptyline, wherein the Alzheimer disease, Metabolic syndrome Parkinson disease neurological the compound, a side involving quenching; Other diseases or disorder to the convulsion, the compound, constrain, wherein the pain, schizophrenia, a reinforcing twitches, comprising a headache, the urine incontinence, wherein the; the meconium peptide preparation of a compound, a disorder of the vomit, the brain, compound of hangfire's disorders, the induction's AIDS dementia, the water-cooling injury, retinopathy, knew, and infects of the composition and a HIV, the upper, function is balance of sports and organ defined.
Term
No projected expiry on record.
- Priority
- Filed
- Granted
- Today
28 members in 14 offices
Priority claims2
| Document | Office | Kind | Date |
|---|---|---|---|
| 51009900 | United States of America | A | |
| 0105967 | United States of America | W |
Members28
| Document | Office | Kind | |
|---|---|---|---|
| CA2400916A1 | Canada | A1 | |
| WO0162706A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU4327101A | Australia | A | |
| US6444702B1 | United States of America | B1 | |
| EP1259477A1 | European Patent Office (EPO) | A1 | |
| US2003008889A1 | United States of America | A1 | |
| BR0108547A | Brazil | A | |
| JP2003523989A | Japan | A | |
| US6620845B2 | United States of America | B2 | |
| CN1446193A | China | A | |
| HK1052921A1 | Hong Kong, China | A1 | |
| US2004029929A1 | United States of America | A1 | |
| AU2001243271B2 | Australia | B2 | |
| EP1259477B1 | European Patent Office (EPO) | B1 | |
| AT294774TThis record | Austria | T | |
| ATE294774T1 | Austria | T1 | |
| DE60110557D1 | Germany | D1 | |
| MXPA02008170A | Mexico | A | |
| EP1568685A1 | European Patent Office (EPO) | A1 | |
| PT1259477E | Portugal | E | |
| ES2243468T3 | Spain | T3 | |
| DE60110557T2 | Germany | T2 | |
| US2006106222A1 | United States of America | A1 | |
| CN100339356C | China | C | |
| US7326730B2 | United States of America | B2 | |
| US2008183003A1 | United States of America | A1 | |
| JP4317343B2 | Japan | B2 | |
| CA2400916C | Canada | C |
2 legal events, as the office reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | |
|---|---|---|
| Ceased due to non-payment of the annual feeCeasedREN | REN | |
| Publication of translation of european patent specificationUEP | UEP |
Numbers
- Application
- 1916217
Titles2
- German
- AMINOADAMANTAN-DERIVATE ALS THERAPEUTISCHE MITTEL
- English
- AMINOADAMANTAN DERIVATIVES AS THERAPEUTIC AGENTS
Classification
- CPC, 21
- C07C233/23
- A61P1/08
- A61P9/02
- A61P9/04
- A61P9/10
- A61P13/10
- A61P17/02
- A61P21/00
- A61P25/00
- A61P25/04
- A61P25/06
- A61P25/08
- A61P25/14
- A61P25/16
- A61P25/22
- A61P25/28
- A61P25/34
- A61P25/36
- A61P27/02
- C07C219/24
- C07C2603/74
- IPC, 35
- A61K31 133
- A61K31 135
- A61K31 164
- A61K31 196
- A61K31 21
- A61K31 221
- A61K31 27
- A61P1 08
- A61P13 10
- A61P17 02
- A61P21 00
- A61P25 00
- A61P25 04
- A61P25 06
- A61P25 08
- A61P25 14
- A61P25 16
- A61P25 22
- A61P25 28
- A61P25 34
- A61P25 36
- A61P27 02
- A61P9 02
- A61P9 04
- A61P9 10
- C07C209 76
- C07C211 38
- C07C213 00
- C07C215 44
- C07C219 24
- C07C231 12
- C07C233 23
- C07C233 52
- C07C269 06
- C07C271 24